Pasithea Therapeutics Corp.

NasdaqCM KTTA

Pasithea Therapeutics Corp. Market Capitalization on January 14, 2025: USD 3.20 M

Pasithea Therapeutics Corp. Market Capitalization is USD 3.20 M on January 14, 2025, a -65.09% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Pasithea Therapeutics Corp. 52-week high Market Capitalization is USD 11.05 M on April 04, 2024, which is 245.68% above the current Market Capitalization.
Pasithea Therapeutics Corp. 52-week low Market Capitalization is USD 3.20 M on January 14, 2025, which is 0.00% below the current Market Capitalization.
Pasithea Therapeutics Corp. average Market Capitalization for the last 52 weeks is USD 6.72 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: KTTA

Pasithea Therapeutics Corp.

CEO	Dr. Tiago Reis Marques M.D., Ph.D.
IPO Date	Sept. 15, 2021
Location	United States
Headquarters	1111 Lincoln Road
Employees	8
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Key trends

Past 5 years